A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 142 participants.

Also called NCT06797869

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 142 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06797869
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Canada, Denmark, France, Norway, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06797869. Randomized; quadruple masking; primary purpose treatment. Start 2025-01-29 (actual); primary completion 2026-06-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy
Condition
Diabetes Mellitus, Type 2
Condition
Diabetic Peripheral Neuropathy
Intervention (Drug)
CagriSema (Cagrilintide B and Semaglutide I)
Intervention (Drug)
Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct06797869
Content hash
ef5fc21945788c9d9ed419832c8dc81688b8f8f7f6fc23d0163918975ecdace1